|Assessment Status||Rapid review complete|
|Indication||For the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older, who are candidates for systemic therapy.|
|Rapid review commissioned||05/07/2021|
|Rapid review completed||29/07/2021|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that upadacitinib should not be considered for reimbursement at the submitted price.*|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations February 2022.